Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Conditions

• Relapsed or Refractory Large B-cell Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Loncastuximab Tesirine — DRUG
  Patients will receive Loncastuximab Tesirine intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
• Rituximab — DRUG
  Rituximab is administered intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.

Study Details

The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.

Key Dates

Start date

Aug 25, 2025

Status verified

May 2026

Primary completion

Mar 31, 2027

Completion

Mar 31, 2030

Study Design

Enrollment

29 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment: All Patients
  The study will investigate the effectiveness of Loncastuximab tesirine and Rituximab (Lonca-R) prior to standard of care CAR-T cell therapy.

Primary Outcome Measure

The complete response (CR) rate at D30 post CAR-T(+/- 7 days) post CAR-T administration per Lugano 2014 criteria. [ Time Frame: 1 month ]

Central Contacts

• Rachel Kingsford
  801-585-0115
  [email protected]
• Narendranath Epperla, MD, MS, FACP
  801-585-0255
  [email protected]

Locations (1)

Find similar trials in Salt Lake City, UT

Related Studies

• Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
  PHASE3 · Recruiting · Kite, A Gilead Company · Stanford, California